A novel formulation of selegiline for the treatment of Parkinson's disease

Neurology

Volumn 63, Issue 7 SUPPL. 2, 2004, Pages

  Tetrud, James W ^a   Koller, William C ^b  

^a PARKINSON S INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; LEVODOPA; NEUROTOXIN; OLANZAPINE; OPIATE; PARGYLINE; SELEGILINE;

ARTHRITIS; BIOTRANSFORMATION; CLINICAL TRIAL; DIET RESTRICTION; DOPAMINERGIC ACTIVITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DYSKINESIA; DYSPEPSIA; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; LONG TERM CARE; MITOCHONDRIAL RESPIRATION; MYASTHENIA; NAUSEA; NERVE CELL; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TACHYCARDIA; THORAX PAIN;

EID: 5144224432     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.7_suppl_2.s2     Document Type: Review

References (33)

1. Barbeau A. Preliminary observations on abnormal catecholamine metabolism in basal ganglia diseases. Neurology 1960;10:446-451.
2. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961;73:787-788.
3. Birkmayer W, Mentasti M. Features of medical therapy of Parkinson's syndrome [in German]. Wien Klin Wochenschr 1962;74:700-702.
4. Knoll J, Ecseri Z, Kelemen K, et al. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155:154-164.
5. Johnson AG. Monoamine oxidase inhibitors. BMJ 1968;2:433.
6. Riederer P, Youdim MBH. Human brain monoamine oxidase activity and monoamine metabolism in Parkinsonian patients treated with 1-deprenyl. J Neurochem 1986;45:1349-1356.
7. Glover V, Elsworth JD, Sandler M. Dopamine oxidation and its inhibition by (-)-deprenyl in man. J Neural Transm Suppl 1980;16:163-172.
8. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408.
9. Youdim MB, Collins GG, Sandler M, et al. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 1972;236:225-228.
10. Birkmayer W, Riederer P, Youdim MB, et al. The potential of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 1975;36:303-326.
11. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet. 1977;2:791-795.
12. Sandler M, Glover V, Ashford A, Stern GM. Absence of "cheese effect" during deprenyl therapy: some recent studies. J Neural Transm 1978;43:209-215.
13. Csanda E, Antal J, Antony M, Csanaky A. Experiences with L-deprenyl in parkinsonism. J Neural Transm 1978;43:263-269.
14. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect.' Psychopharmacology (Berl) 1978;57:33-38.
15. Birkmayer W, Knoll J, Riederer P, Youdim MB. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983;19:170-176.
16. Langston, JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
17. Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydopryidine. Proc Natl Acad Sci USA 1983;80:4546-4550.
18. Chiba K, Trevor AJ, Castagnoli N, et al. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 1985;128:1228-1232.
19. Langston JW, Irwin I, Langston EB, et al. 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984;48:87-92.
20. Langston JW, Irwin I, Langston EB, et al. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
21. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium. J Neurochem 1985;45:1951-1953.
22. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 1983;19:103. Abstract.
23. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-522.
24. Parkinson's Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060.
25. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1997;50:375-382.
26. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1241-1255.
27. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve terminals. Brain Res 1984;303:359-364.
28. Sieradzan K, Channon S, Ramponi C, et al. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in parkinson's disease. J Clin Psychopharmacol 1995;15(4 suppl 2):51S-59S.
29. Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1987;45:111-118.
30. Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces "off" time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-432.
31. Dooneief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-307.
32. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-1077.
33. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997;20:419-433.